Lipoprotein lipase Inhibitors
3 drugsAbout Lipoprotein lipase
Lipoprotein lipase (LPL) hydrolyzes triglycerides in lipoproteins, releasing fatty acids for tissue uptake and energy storage. This enzyme plays a crucial role in lipid metabolism by processing fats in the body.
LPL is a therapeutic target for modulating triglyceride levels, particularly in metabolic disorders. Currently, there is no genetic evidence available linking LPL to specific diseases.
LPL is targeted by 3 FDA-approved small molecule drugs, including VASCEPA, LOVAZA, and OMEGA-3-ACID ETHYL ESTERS. These drugs are developed by Apotex, AMARIN PHARMS, and WAYLIS THERAP.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Breast Atypical Hyperplasia with only 1 trials.
- phase1 represents biological uncertainty with 41% completion.
Top Lipoprotein lipase Drugs
The competitive landscape consists of 3 companies with approved drugs.
Low market concentration suggests opportunities for new entrants, but established players pose a threat.
Lipoprotein lipase Drug Modality Landscape
Modalities
Routes of Administration
Lipoprotein lipase is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or gene therapies could provide a competitive advantage.
Lipoprotein lipase Clinical Trials 62 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 20 | 7 | 13 | 0 | 35% |
| Phase 2 | 16 | 10 | 3 | 3 | 77% |
| Phase 3 | 13 | 8 | 3 | 2 | 73% |
| Phase 4 | 13 | 9 | 4 | 0 | 69% |
Top Sponsors
By Modality
Top Conditions
Lipoprotein lipase Drug Approval Timeline (2004 - 2012)
The first drug targeting LPL was approved in 2004, and the most recent in 2014.
The approval timeline indicates a potentially saturated market, requiring differentiated products for success.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 48 clinical trials targeting Lipoprotein lipase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities